Exelixis Inc’s (EXEL) Stock: A 1.05% Simple Moving Average for the Past 20 Days

In the past week, EXEL stock has gone down by -1.52%, with a monthly gain of 4.95% and a quarterly plunge of -2.71%. The volatility ratio for the week is 2.24%, and the volatility levels for the last 30 days are 1.90% for Exelixis Inc The simple moving average for the past 20 days is 1.05% for EXEL’s stock, with a 8.62% simple moving average for the past 200 days.

Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?

The price-to-earnings ratio for Exelixis Inc (NASDAQ: EXEL) is above average at 36.06x, Company’s 36-month beta value is 0.57.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for EXEL is 294.81M, and currently, short sellers hold a 2.80% ratio of that floaft. The average trading volume of EXEL on April 03, 2024 was 2.36M shares.

EXEL) stock’s latest price update

The stock of Exelixis Inc (NASDAQ: EXEL) has decreased by -1.44 when compared to last closing price of 23.68. Despite this, the company has experienced a -1.52% fall in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-25 that M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma’s balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

Analysts’ Opinion of EXEL

Many brokerage firms have already submitted their reports for EXEL stocks, with BTIG Research repeating the rating for EXEL by listing it as a “Buy.” The predicted price for EXEL in the upcoming period, according to BTIG Research is $27 based on the research report published on December 19, 2023 of the previous year 2023.

Citigroup, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $31. The rating they have provided for EXEL stocks is “Buy” according to the report published on December 15th, 2023.

H.C. Wainwright gave a rating of “Buy” to EXEL, setting the target price at $28 in the report published on September 26th of the previous year.

EXEL Trading at 5.71% from the 50-Day Moving Average

After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.11% of loss for the given period.

Volatility was left at 1.90%, however, over the last 30 days, the volatility rate increased by 2.24%, as shares surge +3.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.83% upper at present.

During the last 5 trading sessions, EXEL fell by -1.52%, which changed the moving average for the period of 200-days by +24.28% in comparison to the 20-day moving average, which settled at $23.14. In addition, Exelixis Inc saw -2.71% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EXEL starting from Garber Alan M, who sale 19,205 shares at the price of $24.01 back on Mar 21 ’24. After this action, Garber Alan M now owns 35,703 shares of Exelixis Inc, valued at $461,112 using the latest closing price.

Haley Patrick J., the EVP, Commercial of Exelixis Inc, sale 47,020 shares at $21.45 during a trade that took place back on Feb 23 ’24, which means that Haley Patrick J. is holding 384,866 shares at $1,008,579 based on the most recent closing price.

Stock Fundamentals for EXEL

Current profitability levels for the company are sitting at:

  • 0.09 for the present operating margin
  • 0.96 for the gross margin

The net margin for Exelixis Inc stands at 0.11. The total capital return value is set at 0.06. Equity return is now at value 8.74, with 6.85 for asset returns.

Based on Exelixis Inc (EXEL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.55. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -6.24.

Currently, EBITDA for the company is 196.6 million with net debt to EBITDA at -0.41. When we switch over and look at the enterprise to sales, we see a ratio of 3.83. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.

Conclusion

In a nutshell, Exelixis Inc (EXEL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts